Purolite and Codexis have entered into a joint collaboration to develop and market immobilized enzymes for the pharmaceutical industry. Pennsylvania-based firm Purolite manufactures ion exchange, catalyst, adsorbent, and specialty resins; Codexis engineers enzymes for pharmaceutical, biofuel, and chemical production.
The companies said this partnership will enable them to develop immobilized transaminase enzymes for use in the production of pharmaceuticals. Enzymes are immobilized through binding to inert resins, allowing for easier separation from a reaction mixture, and immobilization often allows for the use of these enzymes under different conditions and reuse at a commercial scale, the firms said.
“Under this new collaboration with Purolite, we will be launching a kit of immobilized transaminases as an extension of our Codex® screening kits,” said Peter Seufer-Wasserthal, Ph.D., svp, pharmaceuticals at Codexis. “The new immobilized enzyme kits will allow potential customers to quickly assess ideas for biocatalytic processes.”
Alessandra Basso, Ph.D., business manager of the LifeTech™ unit at Purolite, added: “The successful implementation of these ready-to-use immobilized enzymes for fast screening processes opens the door to new concepts of drug development, where scientists who are unfamiliar with biocatalytic processes can easily apply immobilized enzymes to different screening processes that can speed up new molecule and API development.”